Business Standard

Expert panel approves use of Serum Institute's Covovax for 7-11-year olds

India started vaccinating adolescents (aged 15-18) from January, and further expanded the drive to include children as young as 12 years from March

vaccine
Premium

The expert panel had recommended use of Corbevax for children as young as five in April, while it had sought more data from Bharat Biotech for kids in the 2-11-year category

Sohini Das Mumbai
An expert panel advising the Central Drugs Standard Control Organisation (CDSCO) has recommended granting emergency use authorisation (EUA) to Serum Institute of India’s (SII’s) Covovax for use in children aged 7-11, according to sources. 

The Drugs Controller General of India (DCGI) will review this recommendation before granting a final approval. 

Sources indicated that the SEC deliberated upon the matter and recommended an EUA for use in younger children. The process of data review was on for the past few months, after SII submitted trial data from their children’s studies around March.

Covovax — the protein vaccine from US major Novovax

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Jun 24 2022 | 9:28 PM IST

Explore News

To read the full story, subscribe to BS Premium now, at just Rs 249/ month.

Key stories on business-standard.com are available only to BS Premium subscribers.

Register to read more on Business-Standard.com